GET DAILY SIGNALSTvardi Therapeutics (TVRD): The +760% Path to the $10 Analyst Target
Key Takeaways
- The central target of $10 is the arithmetic mean of nine verified analyst price targets reviewed for this article, rounded from a calculated mean of roughly $10.22.
- Individual targets span a wide range from $3 (Barclays, Underweight) to $15 (BTIG, Buy), reflecting sharply divided views on the company's pipeline.
- At a recent price near $1.16, reaching $10 would require a gain of roughly 760% — an exceptionally large move by any standard.
- Supporting factors include a validated STAT3 platform, encouraging Phase 1 data for TTI-109, and a cluster of 2026 analyst upgrades.
- Principal risks are a failed Phase 2 IPF trial, ongoing cash burn, financing-driven dilution, and a market capitalization below $20 million.
- For additional context on this company, explore its Major News and Today's Price Move, review the Forecast, and check the Earnings page.
Understanding the Analyst Consensus
The nine verified targets used here span from a low of $3 to a high of $15, yielding a calculated mean near $10.22, rounded to a $10 central target. The spread is unusually wide, reflecting genuine disagreement about Tvardi's clinical prospects rather than consensus. On the bullish side, BTIG carries a $15 target, Lucid Capital a $14 target, Piper Sandler a $13 target (raised from $3 when it upgraded the stock to Overweight in July 2026), and JonesTrading and Raymond James each carry $10 targets. H.C. Wainwright initiated coverage at $9, while Chardan Capital initiated at $8 in October 2026. The cautious outlier is Barclays, which reiterates an Underweight rating with a $3 target. Cantor Fitzgerald holds a neutral (Hold) rating without a published target.
The July 2026 upgrades followed positive Phase 1 data for TTI-109, a phosphate prodrug of the lead asset TTI-101, which showed rapid conversion and dose-proportional exposure in healthy volunteers. Those catalysts lifted several targets, but the $3-to-$15 range underscores that bullish and cautious analysts are effectively modeling very different outcomes for a company with no approved product. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where the Stock Stands Today
TVRD shares have traded in a 52-week range of roughly $0.77 to $5.69, with the stock recently changing hands near $1.16 and well below its 200-day moving average near $2.62. Reaching $10 from around $1.16 implies a move of about 760%, which must be characterized as very large. The path would depend almost entirely on clinical execution: Tvardi is a pre-revenue company, so traditional valuation anchors such as EPS (earnings per share) or P/E (price-to-earnings) multiples do not apply. Instead, the stock price reflects investors' probability-weighted view of whether its STAT3 programs can eventually generate regulatory approvals and commercial revenue.
Factors That Could Drive It Higher
The core bullish thesis rests on the STAT3 platform and its two lead candidates. TTI-101 is in Phase 1b/2 development for hepatocellular carcinoma (HCC), while TTI-109 is a prodrug designed to improve delivery and tolerability. The July 2026 Phase 1 readout for TTI-109 — showing rapid conversion, dose-proportional pharmacokinetics, and reductions in certain STAT3-driven immune cells — provided early validation and prompted several upgrades. A de-risked HCC data readout or further favorable fibrosis data could materially re-rate a stock with a sub-$20 million market capitalization, where even modest pipeline progress can translate into outsized percentage moves.
Key Risks to Consider
The risks are substantial. In October 2025, Tvardi reported that its Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its primary goals, a setback that reset expectations and contributed to the stock's decline from prior highs. The company generates no revenue and posted a net loss of roughly $26 million over the trailing twelve months, meaning it must continue raising capital — Tvardi has expanded its at-the-market equity program, which creates ongoing dilution risk. A small float, clinical trial risk, and the wide analyst range all suggest the stock can remain volatile and that the higher targets are far from assured.
Technical Picture and Levels to Watch
The 52-week low near $0.77 represents the key long-term support zone, while the $1.00 psychological level and the recent intraday high near $1.60 act as nearer-term reference points. The 52-week high near $5.69 and the 200-day moving average near $2.62 remain well above the current price, indicating a stock in a prolonged downtrend despite periodic spikes in volume and price. A sustained move toward $10 would require not only favorable data but a structural break above multiple resistance levels that have defined the stock's trading range for much of the past year.
Monitoring the Road Ahead
Analyst price targets for Tvardi generally reflect a research horizon of roughly 12 months, though individual firms apply different assumptions about clinical milestones and financing. Investors should monitor the next earnings report and cash-burn disclosures, any updates on the REVERT LIVER CANCER trial for TTI-101 in HCC, additional TTI-109 data, and further financing announcements. Because Tvardi's valuation is clinical-event driven, regulatory feedback, trial enrollment updates, and any changes in analyst ratings or targets are likely to be more meaningful price drivers than traditional quarterly metrics. From what I see, this is important because the outcome hinges on clinical execution rather than near-term financial metrics.
Leveraging Tickeron AI Tools for Research
In my own workflow, I find Tickeron’s AI Daily Buy/Sell Signals helpful for keeping an eye on volatile names like this one. The platform uses artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For a catalyst-driven stock, it offers a systematic way to track potential shifts without relying solely on manual review, complementing fundamental analysis of the pipeline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TVRD in upward trend: price rose above 50-day moving average on November 09, 2026
TVRD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TVRD as a result. In 67 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TVRD just turned positive on October 15, 2026. Looking at past instances where TVRD's MACD turned positive, the stock continued to rise in 29 of 37 cases over the following month. The odds of a continued upward trend are 78%.
Following a +64.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVRD advanced for three days, in 185 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TVRD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TVRD entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (3.498). P/E Ratio (-0.334) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. TVRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TVRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Much Should I Withdraw from my Retirement Accounts Once I Retire?
How Do Pyramid Schemes Work: What Makes Them a Deceptive Business Model?
What are the key differences between VFIAX and SPY, and how do they compare as investment options?
What are the 9 States Without Income Tax and How Do They Impact Your Finances?
What are the top 5 Transamerica Funds?
General Information
Industry Biotechnology
Advertisement